Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration

Retina

Volumn 31, Issue 4, 2011, Pages 636-644

  Bashshur, Ziad F ^a   Schakal, Alex R ^a,b   El Mollayess, Georges M ^a   Arafat, Samer ^a   Jaafar, Dalida ^a   Salti, Haytham I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LENS IMPLANT; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETINA; RETREATMENT; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 79955060859     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181fe54ab     Document Type: Article

References (37)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642. (Pubitemid 15204559)
2. Barouch F, Miller J. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 2004;44:23-32. (Pubitemid 38955658)
3. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-368. (Pubitemid 40942262)
4. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
5. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy (VIP) report 2. Am J Ophthalmol 2001;131:541-560.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch Ophthalmol 2002;120:1307-1314.
7. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-642.
8. Rosenfeld PJ, Brown DM, Heier JS, et al; Marina Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
9. Brown DM, MichelsM, Kaiser PK, Heier JS, Sy JP, Ianchulev T; Anchor Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
10. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
11. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
12. Kaiser PK. Verteporfin photodynamic therapy and antiangiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007;23:477-487. (Pubitemid 46463889)
13. Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 2009;29:133-148.
14. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-874.
15. Kiss CG, Simader C, Michels S, Schmidt-Erfurth U. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the PROTECT study. Br J Ophthalmol 2008;92: 1620-1627.
16. Schmidt-Erfurth U, Wolf S; PROTECT Study Group. Sameday administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-1635.
17. Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study. Retina 2008; 28:1132-1137.
18. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147-2154. (Pubitemid 36520311)
19. Dewi NA, Yuzawa M, Tochigi K, Kawamura A, Mori R. Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area. Jpn J Ophthalmol 2008;52:277-281.
20. Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res 2009;28:145-154.
21. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844. (Pubitemid 34620368)
22. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999; 40:2322-2331. (Pubitemid 29418388)
23. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina 2007;27:713-723. (Pubitemid 47053860)
24. Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol 2008;92:1347-1351.
25. Azab M, Boyer DS, Bressler NM, et al; Visudyne In Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457. (Pubitemid 40489914)
26. Ophthalmology Times Staff Reports. RADICAL study shows positive 12 months reports. Available at: http://ophthalmolo gytimes.modernmedicine.com/ ophthalmologytimes/Clinical+ News/RADICAL-study-shows-positive-12-month-results/ ArticleStandard/Article/detail/603396. Accessed September 27, 2009.
27. Slakter JS, DENALI Study Group. SUMMIT: combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal to AMD. Invest Ophthalmol Vis Sci 2007;48:EAbstract 1817.
28. McNeil R. Anti-VEGF therapy for neovascular AMD: debate on choice and treatment strategies continues. Available at: http://www.pinpointmedical.com/ uploads/pdfs/1395A.pdf. Accessed September 27, 2009.
29. Connolly BP, Rose SJ, Guillet E. Long term results of combination therapy for exudative age related macular degeneration using intraocular bevacizumab and photodynamic therapy with Visudyne: a consecutive case series. Invest Ophthalmol Vis Sci 2007;48:4555.
30. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-3120.
31. Augustin AJ, Puls S, Offerman I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140.
32. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009;29:573-578.
33. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-696.
34. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age- Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study report no. 4. Retina 2004;24:1-12.
35. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27:432-438. (Pubitemid 46624282)
36. Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747-755, 755.e1.
37. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009;29:1067-1073.